16 May 2022
14:22 E.S.T.

Endowing Universal CAR T-cell with Immune-Evasive Properties Using TALEN® -Gene Editing- ASGCT 2022

Download the PDF file

11 Apr 2022
11:16 E.S.T.

UCART20x22: First allogeneic dual CAR T-cell therapy for the treatment of B-cell malignancies - AACR 2022 - PDF abstract

Download the PDF file

10 Apr 2022
16:41 E.S.T.

UCART20x22: First allogeneic dual CAR T-cell therapy for the treatment of B-cell malignancies - AACR 2022 - PDF Poster

Download the PDF file

11 Dec 2021
10:57 E.S.T.

Pre-clinical Development of a Highly Efficient TALEN®- ASH 2021

Download the PDF file

11 Dec 2021
10:55 E.S.T.

Preliminary Results from the Flu/Cy/Alemtuzumab arm of the Phase I BALLI-01 Trial of UCART22- ASH 2021

Download the PDF file

12 Nov 2021
11:45 E.S.T.

Mesothelin (MSLN) Targeting Allogeneic CAR T Cells Engineedred to Overcome Tumor Immunosuppressive Microenvironment- SITC 2021

Download the PDF file

27 Oct 2021
09:18 E.S.T.

Preclinical development of a TALEN-based genome editing in T cells for the treatment of Hyper-IgE-Syndrome - ESGCT 2021

Download the PDF file

27 Oct 2021
09:15 E.S.T.

Preclinical development of a TALEN-based genome editing therapy for RAG1 deficiency - ESGCT 2021

Download the PDF file